Incidental focal colorectal $^{18}$F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography

Soung Hoon Cho, Sang Woo Kim, Won Chul Kim, Jae Myung Park, Ie Ryung Yoo, Sung Hoon Kim, Seong Taek Oh

Soung Hoon Cho, Sang Woo Kim, Won Chul Kim, Jae Myung Park, Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, South Korea
Ie Ryung Yoo, Sung Hoon Kim, Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, South Korea
Seong Taek Oh, Department of Surgery, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, South Korea

Author contributions: Cho SH and Kim SW designed and performed the research; Kim WC, Park JM, Ie RY, Oh ST, Kim SH collected and analyzed the data; Cho SH and Kim SW wrote the paper.

Correspondence to: Sang Woo Kim, MD, Professor of Medicine, Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, South Korea. viper@catholic.ac.kr
Telephone: +82-2-22582083 Fax: +82-2-22582089
Received: December 25, 2012 Revised: March 20, 2013
Accepted: March 28, 2013
Published online: June 14, 2013

Abstract

AIM: To assess the clinical significance of incidental focal colorectal $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) uptake on $^{18}$F-FDG-positron emission tomography/computed tomography (PET/CT).

METHODS: The records of all the cases which had undergone colonoscopy after PET/CT within a two weeks interval were reviewed. Adenomas were considered advanced when they were villous, $\geq 10$ mm in size, or had high-grade dysplasia. Colorectal cancers and advanced adenomas are collectively referred to as advanced colorectal neoplasms. Receiver-operating characteristic curve analysis was used to determine the significant predictive maximum standardized uptake value (SUVmax) cutoff value for advanced colorectal neoplasms and cancer.

RESULTS: Ninety-five colorectal lesions matched the site of incidental focal colorectal $^{18}$F-FDG uptake on PET/CT and 146 did not. Colonoscopy showed advanced colorectal neoplasms corresponding to the site of $^{18}$F-FDG uptake in 49 of the 95 (51.5%) lesions with incidental uptake. Of the lesions without incidental uptake, only 6 of 146 (4.1%) had advanced colorectal neoplasms on colonoscopy, indicating a statistically significant difference between the two groups ($P < 0.001$). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of incidental focal $^{18}$F-FDG uptake in identifying advanced colorectal neoplasms were 89.1%, 75.3%, 51.6%, 95.9%, and 78.4%, respectively. In detecting only CRC, these values were 89.2%, 69.6%, 34.7%, 97.3%, and 72.6%, respectively. The significant SUVmax cutoff value for advanced colorectal neoplasms (area under the curve 0.755, $P < 0.001$) was 4.35, with a sensitivity, specificity, PPV, NPV, and accuracy of 75.5%, 65.2%, 51.6%, 95.9%, and 78.4%, respectively. For CRC, 5.05 was the significant SUVmax cutoff value (area under the curve 0.817, $P < 0.001$), with a sensitivity, specificity, PPV, NPV, and accuracy of 84.8%, 71.0%, 80.9%, 89.8%, and 75.8%, respectively.

CONCLUSION: The presence of incidental focal colorectal $^{18}$F-FDG uptake on PET/CT with a SUVmax $\geq 4.35$ increases the likelihood of an advanced colorectal neoplasm.

© 2013 Baishideng. All rights reserved.

Key words: Positron emission tomography; Adenomas; Computed tomography; Colorectal cancer; Colonoscopy
Incidental focal uptake of $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) in the colon and rectum can be found incidentally during $^{18}$F-FDG-positron emission tomography/computed tomography (PET/CT). The presence of incidental focal colorectal $^{18}$F-FDG uptake on PET/CT indicated advanced colorectal neoplasms in more than half of the cases. Our study confirms the necessity of colonoscopy when incidental FDG uptake is detected on PET/CT to allow the early diagnosis and management of advanced colorectal neoplasms.

**INTRODUCTION**

$^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG)-positron emission tomography/computed tomography (PET/CT) is a technique used to reduce false-positive findings by combining two imaging modalities, and can distinguish physiological activity from pathology more readily than PET or CT alone. PET/CT is commonly used during the evaluation of malignant tumors, and an increased focal colorectal uptake of $^{18}$F-FDG can be observed incidentally because of the capacity of PET/CT to detect the foci of tumors, which display increased glycolysis.

Several previous studies have shown that not only is a high incidence of unexpected gastrointestinal malignancies associated with incidental $^{18}$F-FDG avidity, but also that the presence of these lesions can change patient management in up to 28% of cases. And in asymptomatic patients with proven or suspected colorectal cancer (CRC) recurrence PET detected additional sites of disease in up to 48.4% of patients.

However, the significance of incidental focal colorectal $^{18}$F-FDG uptake observed on PET/CT has not yet been fully clarified. Only one previous prospective study has demonstrated a requirement for colonoscopy when incidental FDG uptake was found with PET/CT imaging. However, those researchers could not determine the statistically significant maximum standardized uptake value (SUVmax) with which to detect advanced colorectal adenoma and cancer because of the broad overlapping SUV values among the patient groups.

As far as we know, we have evaluated the largest number of cases yet assessed to determine the value of colonoscopy when incidental FDG uptake is observed on PET/CT images. In this study, we investigated the clinical significance of incidental focal colorectal $^{18}$F-FDG uptake detected on PET/CT, and determined the SUVmax for detecting advanced adenoma and cancer.

**MATERIALS AND METHODS**

**Patients**

We analyzed the records of 583 consecutive colonoscopic lesions examined over a three-year period, from those who had undergone colonoscopy after PET/CT within a two weeks interval.

The exclusion criteria were an incomplete colonoscopic examination, insufficient biopsy specimen for pathological diagnosis, diffuse colorectal $^{18}$F-FDG uptake on PET/CT, and proven or suspected CRC in a previous study. A surveillance PET/CT examination performed for clinical assessment after curative CRC resection was not an exclusion criterion. Based on these criteria, 342 lesions were excluded.

A total of 241 colonoscopic lesions (88 from women and 153 from men) were eligible for the study. The median age was 62 years (range: 29-86 years). The study was approved by the Institutional Review Board of Seoul St Mary's Hospital, Catholic University of Korea College of Medicine.

**PET/CT acquisition**

The subjects were fasted for at least 6 h before the FDG injection. Their blood glucose levels were determined in capillary blood samples before the intravenous injection of FDG. At our institution, a cutoff blood glucose level of 8 mmol/L contraindicates FDG injection. PET/CT images were acquired 1 h after the injection of 370-570 MBq of $^{18}$F-FDG. The subjects were scanned from the base of the skull to the upper thighs, with their arms raised above their heads.

The PET/CT scans (dual-section helical CT) were performed on a Biograph Duo scanner (Siemens Medical Solutions, Knoxville, TN, United States) with an axial spatial resolution of 6.5 mm. Neither intravenous contrast medium nor bowel preparations were used for the CT scan.

The PET/CT images were reviewed on a workstation with fusion software (Syngo, Siemens, Knoxville, TN, United States). An experienced nuclear medicine physician reviewed the PET/CT images. PET, CT, and fused whole-body images displayed in the axial, coronal, and sagittal planes were available for review. The PET data were also displayed in a rotating maximum-intensity projection. The intensity of the $^{18}$F-FDG uptake can be analysed qualitatively and semiquantitatively by measuring the standardized uptake value, which is usually expressed as its maximum. The SUV is defined as the ratio of activity within the tissue (Bq/mL) and decay-corrected total activity injected divided by body weight (Bq/g) and it is calculated using the software provided by the workstation manufacturer. Abnormal FDG uptake, the SUVmax of the primary tumor, and distant metastases were evaluated.

**PET/CT interpretation and analysis**

PET studies showing focal, well-circumscribed foci of...
increased abdominopelvic \(^{18}\)F-FDG uptake, localized by PET/CT images to the colorectum, and distinguishable from the background colonic uptake, were reviewed for interpretation.\(^{1}\) The incidence of incidental focally increased \(^{18}\)F-FDG uptake in the colorectum was calculated and the intensity of the uptake was measured by calculating SUVmax from the attenuation-corrected PET data, using the software provided by the workstation manufacturer. Lesion size on PET/CT was not part of the inclusion criteria. The PET/CT findings were correlated with the various colonoscopic and histopathological results.

**Colonoscopy and surgery**

Two hundred forty-one colorectal pathological specimens obtained from 212 subjects who had undergone a total colonoscopy were studied. All colorectal lesions that appeared to be of neoplastic origin were biopsied and removed by polypectomy and/or surgery. Colonoscopy with a pathological examination was considered the gold standard diagnostic method.

Adenomas were considered advanced when they were villous, \(\geq 10\) mm in size, or had high-grade dysplasia. Colorectal cancers and advanced adenomas are collectively referred to as advanced colorectal neoplasms. If a subject had more than one detectable colorectal lesion, then each lesion was analyzed individually.

**RESULTS**

**Patient characteristics**

Two hundred forty-one eligible colonoscopic lesions were obtained from 212 individual subjects. Of these, 95 lesions showed incidental focal colorectal \(^{18}\)F-FDG uptake on PET/CT and 146 did not. The characteristics of the 241 colonoscopic lesions evaluated in this study are shown in Table 1. Of these, 153 were male and the mean age was 62 years (range: 29-86 years). The sex, age, and body mass index did not differ significantly between the \(^{18}\)F-FDG positive and negative groups. The indications for PET/CT were as part of the initial staging of malignancies other than CRC in 99 cases, after the complete resection of malignancies other than CRC in 87 cases, and after chemotherapy for malignancies other than CRC in 12 cases. Thirty-one scanned cases were performed during health screening and 12 during screening for other purposes (Table 2).

The pathological diagnoses were 37 cancers, 24 acute or chronic inflammation, 140 non specific, and 18 advanced adenomatous lesions among a total of 40 adenomatous lesions (Table 1).

**Diagnostic accuracy of focal incidental uptake on PET/CT**

In those lesions showing incidental uptake on PET/CT, 49 of 95 (51.5\%) had advanced colorectal neoplasms on colonoscopy corresponding to the site of \(^{18}\)F-FDG uptake, whereas in those lesions without uptake, only 6

---

### Table 1  Baseline characteristics and pathologic diagnoses of the 241 elegible colorectal lesions (n (%))

| Variables                               | Total (n = 241) | Focal FDG uptake (+) (n = 95) | Focal FDG uptake (-) (n = 146) | P value |
|-----------------------------------------|----------------|-------------------------------|-------------------------------|---------|
| **Baseline characteristics**            |                |                               |                               |         |
| Age, yr (range)                         | 62 (29-86)     | 64 (31-86)                    | 59.5 (29-84)                  | 0.068   |
| Males                                   | 153 (64)       | 57 (60)                       | 96 (65)                       | 0.366   |
| Overweight or obesity (BMI > 25 kg/m\(^2\)) | 22 (9.1)    | 9 (9.5)                       | 13 (8.9)                      | 0.367   |
| F/U after complete CRC resection        | 67 (28.2)      | 16 (17.9)                     | 51 (34.9)                     | 0.006   |
| **Pathologic diagnoses**                |                |                               |                               |         |
| Non specific                            | 140 (58.1)     | 26 (27.5)                     | 114 (78.1)                    | \(< 0.001\) |
| Inflammation                           | 24 (9.9)       | 18 (18.9)                     | 6 (4.1)                       | \(< 0.001\) |
| Adenoma (any size)                     | 40 (16.6)      | 18 (18.9)                     | 22 (15.1)                     | 0.430   |
| Advanced adenoma                       | 18 (7.5)       | 16 (16.8)                     | 2 (1.4)                       | \(< 0.001\) |
| Cancer                                  | 37 (15.4)      | 33 (34.7)                     | 4 (2.7)                       | \(< 0.001\) |
| Advanced colorectal neoplasms           | 55 (22.9)      | 49/95 (51.5)                  | 6/146 (4.1)                   | \(< 0.001\) |

\(^{1}\)Median (range). FDG: \(^{18}\)Fluorodeoxyglucose; BMI: Body mass index; F/U: Follow up; CRC: Colorectal cancer.

### Table 2  Positron emission tomography/computed tomograph indications of the eligible colorectal lesions

| Initial cancer staging (n = 99) | After complete resection (n = 87) | After cancer chemotherapy (n = 12) | Health screening (n = 12) | Others (n = 31) |
|---------------------------------|----------------------------------|-----------------------------------|--------------------------|-----------------|
| Stomach: 33                    | Colorectum: 67                  | Stomach: 2                        | Others: 12               | Others: 16      |
| MUO: 19                        | Stomach: 8                      | OBGY: 2                           | Others: 2                |                 |
| OBGY: 12                       |                                  |                                   |                          |                 |
| Lung: 10                       |                                  |                                   |                          |                 |
| Hepatobiliary: 9               |                                  |                                   |                          |                 |
| Others: 16                     |                                  |                                   |                          |                 |

MUO: Metastasis of unknown origin; OBGY: Obstetrics and gynecology.

**Statistical analysis**

The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the incidental focal \(^{18}\)F-FDG uptake in predicting advanced colorectal neoplasms and CRC were calculated. Receiver-operating characteristic (ROC) curve analysis was used to determine the significant predictive SUVmax cutoff value for advanced colorectal neoplasms and cancer. For all tests, a \(P\) value \(< 0.05\) was considered statistically significant. All statistical analyses were performed with SPSS, version 16 (SPSS, Chicago, IL, United States).
of 146 (4.1%) were found to have advanced colorectal neoplasms on colonoscopy. This indicates a statistically significant difference between the two groups (P < 0.001). Overall, the sensitivity, specificity, PPV, NPV, and accuracy of incidental focal $^{18}$F-FDG uptake in predicting advanced colorectal neoplasms were 89.1%, 75.3%, 51.6%, 95.9%, and 78.4%, respectively. For detecting only CRC, the sensitivity, specificity, PPV, NPV, and accuracy of incidental focal $^{18}$F-FDG uptake were 89.2%, 69.6%, 34.7%, 97.3%, and 72.6%, respectively.

**SUVmax and colorectal neoplastic lesions**

The statistically significant SUVmax cutoff value that allowed the discrimination of advanced colorectal neoplasms from non advanced neoplastic and non neoplastic lesions was 4.35 (area under the ROC curve 0.755, P < 0.001), with a sensitivity, specificity, PPV, NPV, and accuracy of 75.5%, 65.2%, 69.8%, 71.4%, and 70.5%, respectively. For CRC, 5.05 was the statistically significant SUVmax cutoff value (area under the curve 0.817, P < 0.001), with a sensitivity, specificity, PPV, NPV, and accuracy of 84.8%, 71.0%, 80.9%, 89.8%, and 75.8%, respectively.

**DISCUSSION**

PET/CT is a well-accepted technique for the diagnosis and staging of several malignancies because it provides more accurate functional and anatomical assessments than CT or other conventional imaging modalities.[8] Some researchers demonstrated that multidetector CT colonography has excellent sensitivity and specificity for lesions < 10 mm. In fact, one study reported superior sensitivity compared to conventional colonoscopy for the detection of adenomas 10 mm or larger (93.8% vs 85.5%)[9]. A recent study looking at the feasibility of FDG-PET/CT colonography in patients with high clinical suspicion of colorectal carcinoma showed promising results in being an “all-in-one” staging modality, but was practically challenging and still required a formal colonoscopy for histopathological confirmation.[9]

Physiological $^{18}$F-FDG uptake within the gastrointestinal tract, with variable intensities and localization patterns, has previously been described. Focal tracer uptake is frequently seen at the gastroesophageal junction, moderate uptake in the stomach, low-intensity uptake in the small bowel, and diffuse or focal uptake in the colon.[9] The mechanisms underlying this physiological activity are unclear. Muscular peristaltic activity, the presence of lymphoid tissue in the cecum, high concentrations of white blood cells in the bowel wall, and/or the presence within the bowel wall of cells secreting $^{18}$F-FDG, especially in cases of cecum distention, have been hypothesized.[9] Increased FDG uptake can also be associated with inflammation, such as enterocolitis[10] or inflammatory bowel disease.[11] In our study, only focal or multifocal FDG findings were considered significant because diffuse uptake is considered to have a physiological origin.

Focal colorectal $^{18}$F-FDG uptake indicates a high (70%-80%) probability of corresponding abnormal histopathological findings.[11-18] Despite this increase in confidence and reduction in the number of suggestive or equivocal lesions, the precise localization of increased $^{18}$F-FDG foci using PET/CT cannot at present resolve the diagnostic dilemma of abnormal tracer uptake in the colorectum. For this reason, we assessed the clinical significance of incidental focal colorectal $^{18}$F-FDG uptake on PET/CT and also determined a clinically useful SUVmax cutoff value for the detection of advanced adenoma and cancer. Our results are consistent with two large studies that showed that PET/CT is a sensitive tool with which to detect premalignant lesions.[15,16] In another previous study, PET/CT had a sensitivity of 74% and a specificity of 84% in the detection of colonic abnormalities.[17] However, that study was limited by its small sample size (39 patients).

Although previous studies have evaluated the etiology of incidental PET/CT findings in the colon,[12,19] we believe that our study contributes to the clinician’s perspective by providing a SUVmax cutoff value that discriminates advanced colorectal neoplasms from non advanced lesions.

Larger series, with 3210 and 2000 patients, identified 20 (12 villous adenomas, six carcinomas, and two tubular adenomas) and 13 abnormalities (seven adenomatous polyps and six carcinomas), respectively, with colonoscopy.[15,16] However, they failed to determine a significant SUVmax cutoff value that would be clinically useful in discriminating advanced colorectal neoplasms from malignant carcinomas. In our study, the cutoff SUVmax value was higher in the CRC group than in the advanced neoplasms group (5.05 vs 4.35, respectively). We showed that the intensity of FDG uptake correlated with the severity of the lesion. This is consistent with the results of previous studies, although in those, the cutoff SUVmax value that allowed advanced and non advanced neoplasms to be distinguished was not determined, whereas this was one of the main goals of our study.[24,25] In the present study, a SUVmax ≥ 4.35 increased the likelihood of advanced colorectal neoplasms and a SUVmax ≥ 5.05 increased the likelihood of CRC.

One limitation of our study was a potential selection bias because we included those cases which had undergone PET/CT for the initial staging of a non colorectal malignancy and those in whom surveillance PET/CT had been performed for clinical assessments after curative CRC resection. However, we believe that our study more accurately reflects the real-life clinical situation by including them. The prevalence of focal colonic lesions in our study is also similar to that in previous studies that have used PET to detect colonic lesions.[19,21,22]

In conclusion, our study shows that advanced colorectal adenomas and malignant carcinomas should be suspected when focal $^{18}$F-FDG uptake is detected by PET/CT and that this is clinically significant in most cases. Incidental focal colorectal $^{18}$F-FDG uptake detected on PET/CT with a SUVmax ≥ 4.35 and a SUVmax
incidental colorectal tumours with 18F-labelled 2-fluoro-2-deoxyglucose positron emission tomography/computed tomography scans: results of a prospective study. Colorectal Dis 2011; 13: e374-e379 [PMID: 21831098 DOI: 10.1111/j.1463-1318.2011.02272.x]

6 Ried CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007; 48: 771-775 [PMID: 17479666 DOI: 10.2967/jnumed.106.037291]

7 Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, Wong RK, Nuagent PA, Mysliwiec PA, Schindler WR. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2191-2200 [PMID: 14657426 DOI: 10.1056/NEJMoa031618]

8 Veit P, Kühle C, Beyer T, Kuehl H, Herborn CU, Börsch G, Stergar H, Barkhausen J, Bockisch A, Antoch G. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006; 55: 68-73 [PMID: 15970580 DOI: 10.1136/gut.2005.064170]

9 Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-314 [PMID: 8916319 DOI: 10.1016/S0001-2998(96)80006-7]

10 Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40: 593-603 [PMID: 10210218]

11 Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995; 20: 434-435 [PMID: 7628148 DOI: 10.1097/00003072-199505000-00012]

12 Neurath MF, Vehling D, Schneck K, Holtmann M, Brockmann H, Helisch A, Orth T, Schrekenberger M, Galle PR, Bartenstein P. Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002; 97: 1978-1985 [PMID: 12190164 DOI: 10.1111/j.1572-0241.2002.00536.x]

13 Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230: 417-422 [PMID: 14699176 DOI: 10.1148/ radiol.230201685]

14 Israel O, Mor M, Guralnik L, Hermoni N, Gaitini D, Bar-Shalom R, Keidar Z, Epelbaum R. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med 2004; 45: 2045-2051 [PMID: 15585480]

15 Taitlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002; 224: 783-787 [PMID: 12202714 DOI: 10.1148/ radiol.2243011214]

16 Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 2003; 23: 4357-4361 [PMID: 14666551]

17 Pandit-Taskar N, Schöder H, Gönen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004; 183: 1143-1147 [PMID: 15385321]

18 Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, Shohtsu A. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001; 42: 899-902 [PMID: 11438616]

19 Kamel EM, Thumshirn M, Trunniger K, Schiesser M, Fried M, Padberg B, Schneiter D, Stoeckli SJ, von Schilthuis GK, Stumpe KD. Significance of incidental 18F-FDG accumulation-

REFERENCES

1 Bar-Shalom R, Valdivia AV, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150-185 [PMID: 10928381 DOI: 10.1053/snmc.2000.7439]

2 Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET/CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004; 24: 1411-1431 [PMID: 15376167 DOI: 10.1148/rg.2405035725]

3 Shreve PD, Arazy Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77, quiz 150-151 [PMID: 9925392]

4 Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, Fulham MJ, Pickhardt PJ, Wu J, Wajswinkel K, Meltzer SJ, von Schulthess GK, Kamel EM, Thumshirn M, Trunniger K, Schiesser M, Fried M, Padberg B, Schneiter D, Stoeckli SJ, von Schilthuis GK, Stumpe KD. Significance of incidental 18F-FDG accumulation-

COMMENTS

Background

Positron emission tomography (PET)/computed tomography (CT) is commonly used during the evaluation of malignant tumors. Increased focal uptake of 18F-fluorodeoxyglucose (18F-FDG) in the colon and rectum can be found incidentally during FDG-PET/CT.

Research frontiers

Several previous studies have shown that not only is a high incidence of unexpected gastrointestinal malignancies associated with incidental 18F-FDG avidity, but also that the presence of these lesions can change patient management. However, the significance of incidental focal colorectal 18F-FDG uptake observed on PET/CT has not yet been fully clarified.

Innovations and breakthroughs

The authors have evaluated the largest number of cases yet assessed to determine the value of colonoscopy when incidental FDG uptake is detected on PET/CT images. In this study, the authors investigated the clinical significance of incidental focal colorectal 18F-FDG uptake detected on PET/CT, and determined the maximal standardized uptake value (SUVmax) for detecting advanced adenoma and cancer.

Applications

This study shows that advanced colorectal adenomas and malignant carcinomas should be suspected when focal 18F-FDG uptake is detected by PET/CT and that this is clinically significant in most cases. This study confirms the necessity of colonoscopy when incidental FDG uptake is detected on PET/CT to allow the early diagnosis and management of advanced colorectal neoplasms.

Terminology

FDG-PET/CT display increased sites of glycolysis and by increased focal colorectal uptake of 18F-FDG and is capable to detect the foci of tumors. The SUVmax of 18F-FDG is a way to measure the intensity of the 18F-FDG uptake during FDG-PET/CT. It is measured using the software provided by the FDG-PET/CT workstation manufacturer.

Peer review

The authors assessed the clinical significance of incidental focal colorectal 18F-FDG uptake on FDG-PET/CT. The accuracy of incidental focal 18F-FDG uptake in identifying advanced colorectal neoplasms and colorectal cancer (CRC) were 78.4% and 72.6%, respectively. In addition, they demonstrated higher cutoff SUVmax value in the CRC group than in the advanced neoplasms group (5.05 vs 4.35, respectively).
Cho SH et al. Incidental {\textsuperscript{18}}F-FDG uptake on PET/CT

tions in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45: 1804-1810 [PMID: 15534047]

20 Lee ST, Tan T, Poon AM, Toh HB, Gill S, Berlangieri SU, Kraft E, Byrne AJ, Pathmaraj K, O’Keefe GJ, Tebbutt N, Scott AM. Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-D-glucose-avid colon lesions. Mol Imaging Biol 2008;

21 Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005; 46: 758-762 [PMID: 15872347]

22 Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46: 752-757 [PMID: 15872346]